The cytotoxic reactivity of lymphocytes for autologous melanoma cells was studied in a group of 13 melanoma patients. No cytotoxicity was observed with lymphocytes freshly isolated from peripheral blood or with lymphocytes cocultured for 7 days with autologous melanoma cells. Growth of lymphocytes previously sensitized with autologous melanoma in vitro in interleukin 2 (IL-2)-containing medium, however, resulted in cytotoxic reactivity for autologous melanoma in 7/13 patients. The reactivity of IL-2-dependent lymphocytes for autologous melanoma was particularly striking in one patient (A.V.) who has had an unexpectedly favorable clinical course and, because of their consistently high reactivity, AV lymphocytes were selected for detailed specificity analysis. After 2-3 weeks in culture in IL-2-containing medium, AV lymphocytes were cytolytic for autologous melanoma cells but not autologous Epstein-Barr virus-transformed B cells, autologous fiibroblasts, or allogeneic tumor targets. Specificity of autologous melanoma reactivity was confirmed by competitive inhibition assays. The IL-2-dependent AV lymphocytes formed rosettes with sheep erythrocytes and expressed OKT 3 and Ia antigens. After longer periods of culture, AV lymphocytes were found to react with a wider range of target cells, and repeated attempts to isolate cultures with restricted reactivity to autologous melanoma by resensitization with autologous melanoma and limiting-dilution techniques were unsuccessful. The restricted reactivity of early cultures could be preserved, however, in frozen storage, but shifted again toward broader reactivity after several weeks in culture. The recognition of cytotoxic T cells with initial restricted reactivity for autologous melanoma suggests reinvestigation of the question of specific cellular immunity to human cancer.
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Few topics in cancer research have received as much attention as the issue of tumor-specific antigens. In the case of tumors in experimental animals, the individually distinct antigens of chemically induced tumors, demonstrable by their ability to induce transplantation resistance in syngeneic hosts, represent the most critical and still most compelling evidence for antigens that appear to be restricted to cancer cells (1) . In the case of human cancer, the search for cancerspecific antigens has taken two general approaches. One involves the analysis of heteroantibody to human cancer cells, and this approach has identified a number of quantitative antigenic differences between normal and malignant cells. None of the antigens identified to date by heteroantibody have been tumor specific. However, the advent of hybridoma technology has given new impetus and promise to the use of heteroantibodies as probes for tumor antigens. (3) (4) (5) (6) (7) . Although defining specificity is relatively straightforward using serological methods, analyzing specificity of T-cell reactions to autologous tumor cells is far more difficult. The most extensive study to date is that of Livingston et al. (8) , who examined the cytotoxicity of peripheral blood lymphocytes for autologous cultured melanoma cells in 32 patients. Eighteen patients showed autologous reactivity that appeared to correlate with more limited disease and better clinical prognosis. In these studies, a major problem in defining the specificity of cell-mediated cytotoxic responses was the limited supply of effector cells. With the recognition of T-cell growth factor (interleukin 2, IL-2) (9, 10), it should be possible to overcome this difficulty, as cultures of functional T cells can be cloned and propagated for extended periods.
In the present study, we have examined the generation and specificity of IL-2-dependent cytotoxic T cells sensitized in vitro with autologous melanoma cells.
MATERIALS AND METHODS
Patients. All patients studied had recurrent or metastatic malignant melanoma. The patient selected for detailed study (A.V.) is a 31-year-old male who underwent resections of extensive metastatic melanoma of axillary, supraclavicular, and cervical lymph nodes in 1976 and 1978 and has remained free of detectable melanoma since that time. From 1976 to 1978, the patient's lymphocytes were found to be strongly cytotoxic for autologous cultured melanoma cells on several occasions (8) . At The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Nat. Acad Sci. USA 81 (1984) (ME medium) supplemented with 2 mM glutamine, 1% nonessential amino acids, penicillin at 100 international units/ml, streptomycin at 100 ,g/ml, and 10% prescreened fetal bovine serum (complete medium, CM (9) .
Cell-Mediated Cytotoxicity Assay. Target cells growing as monolayers were cultured in tissue culture flasks (3013, Falcon Plastics) to 80% confluence, washed in complete ME medium and incubated with 200 ,Ci of Na251CrO4 (1 Ci = 37 GBq; New England Nuclear, Boston, MA) in 1 ml of ME medium for 2 hr at 370C in 5% CO2/95% air. Target cells growing in suspension culture were labeled in a similar fashion at a cell concentration of 2 x 106/ml in 0.5 ml of RPMI 1640 medium. After labeling, target cells growing as adherent monolayers were detached by treatment with 0.05% EDTA in phosphate-buffered saline. No cytotoxicity against autologous melanoma cells was detected with PBL co-cultured for 7 or 9 days with autologous tumor in the absence of exogenous IL-2. However, after outgrowth of lymphocytes in IL-2 CM, cytotoxic reactivity of 20-60o specific lysis of autologous melanoma cells at E:T ratios of 40:1 was observed in 7/13 patients. High levels of cytotoxicity could be generated most regularly with cultured lymphocytes from patient A.V. For this reason, the reactivity of AV lymphocytes was selected for detailed analysis.
Growth Characteristics of AV Lymphocytes in IL-2 CM. After co-culture with autologous melanoma cells for 7 days, AV lymphocytes placed in IL-2 CM showed initial proliferation, followed by a lag phase of 3-5 weeks, followed by renewed proliferation. In contrast, AV lymphocytes co-cultured with AV EBV-transformed B cells or AV skin fibroblasts ceased to grow after approximately 1 month of culture in IL-2 CM. When irradiated Daudi cells were added to AV lymphocytes co-cultured with autologous melanoma cells, subsequent lymphocyte proliferation in IL-2 CM was often sustained without an initial intervening lag phase. Lympho- cytes sensitized with autologous AV melanoma.
The specificity of AV lymphocytes for autologous melanoma cells was repeatedly confirmed in competitive inhibition assays. As shown in Fig. 1 , AV lymphocyte cytotoxicity for autologous AV melanoma could be inhibited by AV melanoma but not by autologous EBV-transformed B cells or by allogeneic melanoma cells, renal cancer cells, EBV-transformed B cells, or Daudi cells.
Change in the Cytotoxic Reactivity of Melanoma-Sensitized AV Lymphocytes During Long-Term Culture. The reactions of two independently derived cultures of AV effector cells (AV5 and AV7) grown in IL-2-containing medium for various periods are shown in Fig. 2 . AV5 lymphocytes cultured for 22 days showed a restricted pattern of cytotoxicity-i.e., cytotoxicity for autologous AV melanoma cells but not for the allogeneic target cells. After 27-34 days in culture, AV5 lymphocytes began to show cytotoxicity for AG renal cancer and BD melanoma at a high E:T ratio, and by 49 days cytotoxicity for AG renal cancer was as strong as it was for autologous melanoma. With longer culture, autologous melanoma reactivity of AV5 disappeared whereas cytotoxicity for AG renal cancer persisted at high levels. In the case of lymphocytes from AV7 culture, a similar pattern of shift in cytotoxic reactivity against autologous and allogeneic target cells was observed. The initial restricted cytotoxicity against AV melanoma gradually ceased and reactivity against AG renal cancer cells increased. After prolonged culture (>150 days), reactivity of AV lymphocytes against allogeneic target cells decreased or disappeared. Efforts to preserve the restricted pattern of cytotoxicity by repeated restimulation of AV lymphocytes with autologous melanoma cells were unsuccessful.
Reactivity lution from an 11-day IL-2 CM culture of AV lymphocytes (after a 9-day in vitro sensitization period with autologous AV melanoma) with restricted cytotoxicity for autologous melanoma are shown in Fig. 3 . At the time of the tests with lymphocyte subcultures shown in Fig. 3 , the parental culture AV7 showed a strong preferential cytotoxicity for autologous AV melanoma targets and weaker cross-reactivity with allogeneic AG renal cancer cell targets (as shown in Fig. 2B,  days 26-41 ). The subcultures were tested at 28 days (SC 15), 33 (2) . These studies of cellular and humoral immune reactions in patients with melanoma have focused on patients with stage II or more advanced disease, because of the difficulty of obtaining sufficient tissue from patients with primary melanoma to establish tissue culture lines. A comparable study of a series of patients with primary melanoma will be instructive to determine whether the frequency of specific immune reactions will be higher in patients with more limited disease. As patient A.V. has had a remarkable clinical course, with prolonged survival in the face of advanced disease, it will be important to identify other patients with similar T-cell reactivity for autologous melanoma cells and determine whether a correlation with survival will be found. In addition, the nature of the target cell in detecting immune reactions in melanoma patients needs to be stressed, as emphasized in the studies of Albino et al. (11) .
Of melanoma cell lines derived from six separate metastases of a single patient, only one line expressed sufficient antigen to detect autologous antibody. From these and other considerations (see ref. 12) , it is evident that an assessment of the frequency, specificity, and significance of humoral and cellular reactions against autologous melanoma has barely begun. In this context, it is encouraging that Mukherji and MacAlister (13) have recently reported another melanoma patient with autologous T-cell cytotoxicity showing restricted specificity.
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